NCT05983159 2026-02-19
TARGET-VM
Murdoch Childrens Research Institute
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT03138070 2026-01-28
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT06083038 2025-12-31
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
HealthPartners Institute
Active not recruiting